The Z isomer of the new constrained analog of the anticancer drug octreotide, where L,L-cystine is replaced by 4,5-dehydro-L,L-diaminosuberic acid, was prepared by solid-phase ring-closing metathesis. NMR study ascertained that this molecule is conformationally very close to the parent octreotide and remains unaffected by the enzymatic pool of the human serum for more than 30 h. © 2005 Bentham Science Publishers Ltd.
Synthesis of a Dicarba-Analog of Octreotide Keeping the Type II Beta-Turn of the Pharmacophore in Water Solution / Carotenuto, Alfonso; D'Addona, D; Rivalta, E; Chelli, M; Papini, A. M.; Rovero, P; Ginanneschi, M.. - In: LETTERS IN ORGANIC CHEMISTRY. - ISSN 1570-1786. - STAMPA. - 2:(2005), pp. 274-279. [10.2174/1570178053765276]
Synthesis of a Dicarba-Analog of Octreotide Keeping the Type II Beta-Turn of the Pharmacophore in Water Solution
CAROTENUTO, ALFONSOPrimo
;
2005
Abstract
The Z isomer of the new constrained analog of the anticancer drug octreotide, where L,L-cystine is replaced by 4,5-dehydro-L,L-diaminosuberic acid, was prepared by solid-phase ring-closing metathesis. NMR study ascertained that this molecule is conformationally very close to the parent octreotide and remains unaffected by the enzymatic pool of the human serum for more than 30 h. © 2005 Bentham Science Publishers Ltd.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
